Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
This week in Biotech
Biotech — Sep 7 – Sep 11, 2026 (Wk 37): Biotech Risk Score Rises; Novartis Faces Setback, Encoded Therapeutics Sees Investment →The biotech sector's risk score increased this week, indicating a potentially more volatile environment. Novartis experienced a clinical trial failure, while RTW Biotech Opportunities made an additional investment in Encoded Therapeutics, highlighting continued activity in specific…
CRIS
Valuation N/A
CURIS INC
Price$1.13
Model IV—
P/IV—
Market implies +28.7%/yr
vs model +2.0% · above model
CRL
Deeply overvalued
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Price$278.26
Model IV$114.49
P/IV1.58
Premium +143%
Return to IV: -58.9%
Market implies +16.9%/yr
vs model +5.0% · above model
CRMD
Valuation N/A
CorMedix Inc.
Price$7.83
Model IV—
P/IV—
Limited data — see page
CRSP
Valuation N/A
CRISPR Therapeutics AG
Price$51.72
Model IV—
P/IV—
Market implies +150.0%/yr
vs model +2.0% · above model
CRVO
Valuation N/A
CervoMed Inc.
Price$2.57
Model IV—
P/IV—
Market implies +22.6%/yr
vs model +15.0% · above model
CRVS
Valuation N/A
Corvus Pharmaceuticals, Inc.
Price$12.91
Model IV—
P/IV—
Limited data — see page
CSBR
Deeply undervalued
CHAMPIONS ONCOLOGY, INC.
Price$5.10
Model IV$11.38
P/IV0.51
Discount 55%
Return to IV: +123.2%
Market implies -4.6%/yr
vs model +9.5% · below model
CTKB
Deeply overvalued
Cytek Biosciences, Inc.
Price$4.61
Model IV$1.73
P/IV2.42
Premium +167%
Return to IV: -62.5%
Market implies +12.5%/yr
vs model +12.0% · in line
CTMX
Valuation N/A
CytomX Therapeutics, Inc.
Price$3.29
Model IV—
P/IV—
Market implies +21.4%/yr
vs model +19.5% · in line
CTOR
Valuation N/A
CITIUS ONCOLOGY, INC.
Price$0.94
Model IV—
P/IV—
Limited data — see page
CTXR
Valuation N/A
Citius Pharmaceuticals, Inc.
Price$0.58
Model IV—
P/IV—
Market implies +67.7%/yr
vs model +15.0% · above model
CUE
Valuation N/A
Cue Biopharma, Inc.
Price$30.55
Model IV—
P/IV—
Market implies +92.7%/yr
vs model +16.4% · above model
CURX
Valuation N/A
Curanex Pharmaceuticals Inc
Price$4.55
Model IV—
P/IV—
Limited data — see page
CVKD
Valuation N/A
Cadrenal Therapeutics, Inc.
Price$1.09
Model IV—
P/IV—
Limited data — see page
CVM
Valuation N/A
CEL SCI CORP
Price$1.49
Model IV—
P/IV—
Limited data — see page
CYCN
Valuation N/A
Cyclerion Therapeutics, Inc.
Price$23.94
Model IV—
P/IV—
Market implies +106.6%/yr
vs model +2.0% · above model
CYDY
Valuation N/A
CytoDyn Inc.
Price$0.20
Model IV—
P/IV—
Market implies +93.8%/yr
vs model +15.0% · above model
CYPH
Valuation N/A
CYPHERPUNK TECHNOLOGIES INC.
Price$2.27
Model IV—
P/IV—
Market implies +74.8%/yr
vs model +15.0% · above model
CYRX
Valuation N/A
Cryoport, Inc.
Price$15.55
Model IV—
P/IV—
Market implies +47.6%/yr
vs model +2.0% · above model
CYTK
Deeply undervalued
CYTOKINETICS INC
Price$73.77
Model IV$1,068.82
P/IV0.07
Discount 93%
Return to IV: +1,348.9%
Market implies -50.0%/yr
vs model +5.7% · below model
DARE
Valuation N/A
Dare Bioscience, Inc.
Price$0.71
Model IV—
P/IV—
Market implies +7.4%/yr
vs model +15.0% · below model
DBVT
Valuation N/A
DBV Technologies S.A.
Price$11.85
Model IV—
P/IV—
Market implies +93.1%/yr
vs model +2.0% · above model
DCOY
Valuation N/A
Decoy Therapeutics Inc.
Price$2.67
Model IV—
P/IV—
Limited data — see page
DFTX
Valuation N/A
Definium Therapeutics, Inc.
Price$38.89
Model IV—
P/IV—
Limited data — see page
DH
Fairly valued
Definitive Healthcare Corp.
Price$1.05
Model IV$0.95
P/IV0.98
Premium +10%
Return to IV: -9.3%
Market implies +7.6%/yr
vs model +10.5% · in line
DMAA
Valuation N/A
Drugs Made In America Acquisition Corp.
Price$10.80
Model IV—
P/IV—
Limited data — see page
DMAAU
Valuation N/A
Drugs Made In America Acquisition Corp.
Price$10.79
Model IV—
P/IV—
Limited data — see page
DMAC
Valuation N/A
DiaMedica Therapeutics Inc.
Price$6.47
Model IV—
P/IV—
Limited data — see page
DMII
Valuation N/A
Drugs Made In America Acquisition II Corp.
Price$10.16
Model IV—
P/IV—
Limited data — see page
DMIIR
Valuation N/A
Drugs Made In America Acquisition II Corp.
Price$0.08
Model IV—
P/IV—
Limited data — see page
DMRA
Valuation N/A
Damora Therapeutics, Inc.
Price$28.39
Model IV—
P/IV—
Limited data — see page
DNA
Valuation N/A
Ginkgo Bioworks Holdings, Inc.
Price$6.75
Model IV—
P/IV—
Market implies +54.2%/yr
vs model +2.0% · above model
DNLI
Valuation N/A
Denali Therapeutics Inc.
Price$21.09
Model IV—
P/IV—
Market implies +33.7%/yr
vs model +15.0% · above model
DNTH
Valuation N/A
Dianthus Therapeutics, Inc. /DE/
Price$106.20
Model IV—
P/IV—
Market implies +116.9%/yr
vs model +15.0% · above model
DOC
Undervalued
HEALTHPEAK PROPERTIES, INC.
Price$20.16
Model IV$25.57
P/IV0.75
Discount 21%
Return to IV: +26.8%
DRMA
Valuation N/A
Dermata Therapeutics, Inc.
Price$1.19
Model IV—
P/IV—
Limited data — see page
DRUG
Valuation N/A
BRIGHT MINDS BIOSCIENCES INC.
Price$63.38
Model IV—
P/IV—
Limited data — see page
DSGN
Valuation N/A
Design Therapeutics, Inc.
Price$14.63
Model IV—
P/IV—
Limited data — see page
DTIL
Valuation N/A
PRECISION BIOSCIENCES INC
Price$7.17
Model IV—
P/IV—
Market implies +24.1%/yr
vs model +2.0% · above model
DWTX
Valuation N/A
Dogwood Therapeutics, Inc.
Price$1.94
Model IV—
P/IV—
Limited data — see page
DYAI
Valuation N/A
DYADIC INTERNATIONAL INC
Price$0.48
Model IV—
P/IV—
Market implies +20.3%/yr
vs model +6.5% · above model
DYN
Valuation N/A
Dyne Therapeutics, Inc.
Price$18.21
Model IV—
P/IV—
Limited data — see page
EDIT
Valuation N/A
Editas Medicine, Inc.
Price$2.70
Model IV—
P/IV—
Market implies +46.4%/yr
vs model +12.2% · above model
EDSA
Valuation N/A
Edesa Biotech, Inc.
Price$4.23
Model IV—
P/IV—
Limited data — see page
EIKN
Valuation N/A
Eikon Therapeutics, Inc.
Price$8.94
Model IV—
P/IV—
Limited data — see page
ELTX
Valuation N/A
Elicio Therapeutics, Inc.
Price$1.99
Model IV—
P/IV—
Market implies +34.0%/yr
vs model +15.0% · above model
ELUT
Deeply overvalued
ELUTIA INC.
Price$0.81
Model IV$0.35
P/IV3.33
Premium +132%
Return to IV: -57.0%
Market implies +2.0%/yr
vs model +2.0% · in line
ELVN
Valuation N/A
Enliven Therapeutics, Inc.
Price$54.32
Model IV—
P/IV—
Limited data — see page
ENGN
Valuation N/A
enGene Therapeutics Inc.
Price$1.80
Model IV—
P/IV—
Limited data — see page
ENGNW
Valuation N/A
enGene Therapeutics Inc.
Price$0.23
Model IV—
P/IV—
Limited data — see page
ENTX
Valuation N/A
Entera Bio Ltd.
Price$2.84
Model IV—
P/IV—
Market implies +131.4%/yr
vs model +2.0% · above model
ENVB
Valuation N/A
Enveric Biosciences, Inc.
Price$1.42
Model IV—
P/IV—
Limited data — see page
EQ
Valuation N/A
Equillium, Inc.
Price$2.11
Model IV—
P/IV—
Market implies +2.1%/yr
vs model +15.0% · below model
ERAS
Valuation N/A
Erasca, Inc.
Price$16.16
Model IV—
P/IV—
Limited data — see page
ERNA
Valuation N/A
Ernexa Therapeutics Inc.
Price$4.17
Model IV—
P/IV—
Market implies +35.2%/yr
vs model +15.0% · above model
ESLA
Valuation N/A
Estrella Immunopharma, Inc.
Price$0.66
Model IV—
P/IV—
Limited data — see page
ESLAW
Valuation N/A
Estrella Immunopharma, Inc.
Price$0.07
Model IV—
P/IV—
Limited data — see page
EVAX
Valuation N/A
Evaxion A/S
Price$3.13
Model IV—
P/IV—
Limited data — see page
EVGN
Valuation N/A
Evogene Ltd.
Price$0.48
Model IV—
P/IV—
Limited data — see page
EVMN
Fairly valued
Evommune, Inc.
Price$10.43
Model IV$10.58
P/IV2.19
Discount 1%
Return to IV: +1.5%
Market implies +0.4%/yr
vs model +50.0% · below model